CRESCENT BIOPHARMA, INC. - 10-Q Filing
Crescent Biopharma reports Q3 2026 financial results including significant equity activity and ongoing R&D expenses.
Tickers: $CBIO
Read the full article at SEC EDGAR
Part of the story Immix Biopharma, Inc. - 10-Q Filing (3 articles)